NCT05727904Phase 3Recruiting

Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

Study sponsor: Iovance Biotherapeutics, Inc. · IOVA

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2028-03-01Estimated
Enrollment · participants670Estimated
Source updated2026-09-24Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.